MedTrace Logo

PPIs and Gastroesophageal Varices in Liver Cirrhosis (PPIs: Proton Pump Inhibitors)

NCT03175731 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 106

Last updated 2021-06-09

Study results available
· View outcomes & findings →

Summary

This study is aimed at investigating the effect of PPIs on gastroesophageal varices in liver cirrhosis. Half of participants will receive PPI, while the other half will receive a placebo.

Conditions

Interventions

DRUG

Proton Pump Inhibitors

Pantoprazole 40mg per day intravenously or orally for 2 weeks after endoscopic treatment.

DRUG

Placebo

Placebo 40mg per day intravenously or orally for 2 weeks after endoscopic treatment.

Sponsors & Collaborators

  • Yanjing Gao

    lead OTHER

Principal Investigators

  • Yanjing /A Gao, PhD.MD · Qilu Hospital, Shandong University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-05-01
Primary Completion
2019-08-30
Completion
2019-08-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03175731 on ClinicalTrials.gov